Bioavailability of Protein and Amino Acids of Pea Protein Isolate in Healthy Volunteers (Qualipois)

May 31, 2022 updated by: Robert Benamouzig, Institut National de la Recherche Agronomique

The study aims to determine in healthy subjects the bioavailability of protein and amino acids of pea protein isolate and casein isolate. For this purpose, the investigators will compare two methods:

  1. the standard method consisting in measuring the ileal digestibility using ileal tubes,
  2. an alternative method that has been proposed by an Food and Agriculture Organization (FAO) expert group: the dual isotope method.

Study Overview

Status

Completed

Conditions

Detailed Description

2 groups of healthy volunteers are recruited (males and females from 18 to 65 y old), BMI from 18 to 30.

Each group tests a protein source (30g) incorporated in a mashed potatoes that is divided in small portions to perform a repeated meal protocol. Protein sources (pea or casein) are intrinsically labeled with 15N and deuterium (2H).

The day before the meal test, the volunteers are equipped with an intestinal tube that migrates until the ileum. On the day of the experiment, the position of the intestinal tube is checked by radiography in order to verify its location at the terminal ileum. A catheter is inserted in the forearm vein for blood sampling. A saline solution containing polyethylene glycol 4000 (PEG-4000, 20 g/L), used as a non-absorbable marker of the intestinal flow, is infused into the ileum in order to calculate the flow rate of the intestinal effluents. After a basal blood and urine sampling, as well as a basal collection of ileal effluents performed for 30 min, subject ingests at t=0 the first biscuit dose. The small meal portions are ingested every 30 min for 4h, to achieve an isotopic plateau. Tracer doses of carbon 13 (13C) amino acids are ingested concomitantly with the meal doses. Non-absorbable marker (inulin) is added to the test meal to correct for incomplete recovery at the ileal level.

The postprandial sampling period lasts for 8 h after the meal ingestion. The intestinal content is continuously collected over ice and pooled every 30 min. Blood is sampled every 30 min for 4 h, and hourly thereafter.Total urine is collected every 2 h.

Measurements:

In the effluents, the investigators measure PEG 4000, nitrogen (N) and 15N, carbon and 13C, amino acids (AA), 15N and 13C in amino acids and the non-absorbable markers of the meal. The investigators calculate the ileal flow rate, the overall real ileal protein digestibility and the real ileal digestibility of individual amino acids.

In the plasma, the investigators measure uremia and 15N in urea, AA and protein to measure the transfer of dietary N in plasma protein pools; 15N, 2H and 13C in individual amino acids too measure the relative bioavailability of 15N/2H amino acids compared to free 13C amino acids.

In the urine, the investigators measure urea and 15N in the urea ammonia to calculate the postprandial deamination losses.

These measurements will allow to determine the protein and amino acid bioavailability from pea protein and compare it with casein, using the classical method implying ileal sampling and intrinsic tracer of dietary protein (15N). Additionally, it will allow to test a less invasive procedure using multiple tracers to assess the amino acid bioavailability.

Study Type

Interventional

Enrollment (Actual)

28

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ile-de-france
      • Bobigny, Ile-de-france, France, 93000
        • Centre de Recherche sur Volontaires (CRV)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18<BMI<30
  • Healthy
  • Insured under the French social security system
  • For women: use of birth control
  • Signed informed consent

Exclusion Criteria:

  • Any dietary allergy
  • Latex allergy
  • Positive serology to HIV, hepatite C virus antibody, hepatite B virus surface antigen and core antibodies
  • Gluten intolerance
  • Anemia
  • Use of drugs
  • High consumption of alcohol
  • Hypertension, diabetes, digestive disease, hepatic or renal disease, severe cardiac disease
  • Pregnancy
  • High sport practicing (>7h/wk)
  • Blood donation in the 3 months prior to the study
  • Participation in a clinical study in the 3 months prior to the study
  • No signed informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pea
Mashed potatoes meal containing pea protein isolate intrinsically labelled with 15N and 2H
Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
Active Comparator: Casein
Mashed potatoes meal containing casein isolate intrinsically labelled with 15N and 2H
Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of ileal digestibility of pea proteins and casein
Time Frame: -30 minute to 8 hours after the meal
Total N and 15N will be measured by Elemental Analyzer coupled to an Isotopic Ratio Mass Spectrometer (EA-IRMS) and the percentage of dietary N reaching the terminal ileum will be then determined. This percentage will be corrected by the ileal flow rate which is estimated with measurement of PEG concentration in effluents by a turbidimetric methods. Ileal digestibility of pea proteins and casein (i.e. N digestibility) will be calculated as 100 - corrected dietary N percentage.
-30 minute to 8 hours after the meal
Percentage of ileal digestibility of amino acids from pea proteins and casein
Time Frame: -30 minute to 8 hours after the meal
Amino acid concentrations will be measured by Ultra High Performance Liquid Chromatography (UHPLC) and 15N, 2H and 13C enrichment in individual amino acids will be measured by Gas Chromatography-Combustion-Isotope Ratio Mass Spectrometry (GC-C-IRMS) in order to determine the percentage of dietary individual amino acids reaching the terminal ileum. This percentage will be corrected by the ileal flow rate which is estimated with measurement of PEG concentration in effluents by a turbidimetric methods. Ileal digestibility of pea and casein amino acid will be calculated as 100 - corrected dietary amino acid percentage.
-30 minute to 8 hours after the meal
Percentage of net postprandial protein utilization of pea proteins and casein
Time Frame: -30 minute to 8 hours after the meal
Urea in plasma and urine (by enzymatic methods) will be determined and associated with 15N enrichment values (by EA IRMS) to determine the 15N transfer in plasma and urinary N pools and calculate the net postprandial protein utilization of pea protein and casein.
-30 minute to 8 hours after the meal
Postprandial concentration of dietary amino acids in plasma
Time Frame: -30 minute to 8 hours after the meal
Concentration of individual amino acids (alanine, arginine, asparagine, aspartic acid, cystein, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, proline, phenylalanine, serine, threonine, valine, tryptophan, tyrosine) in plasma will be determined by UHPLC and associated with 15N enrichment values in individual amino acids (by GC C IRMS) to determined the concentration of dietary amino acids in plasma that comes from pea proteins and casein.
-30 minute to 8 hours after the meal
Postprandial concentration of glucose in plasma
Time Frame: -30 minute to 8 hours after the meal
Concentration of glucose (by enzymatic assay) will be determined in plasma.
-30 minute to 8 hours after the meal
Postprandial concentration of insulin in plasma
Time Frame: -30 minute to 8 hours after the meal
Concentration of insulin (by ELISA) will be determined in plasma.
-30 minute to 8 hours after the meal

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Validation of the dual isotope method to assess the bioavailability of individual amino acids
Time Frame: -30 minute to 8 hours after the meal
Measurements of 15N, 2H and 13C amino acids in the plasma by GC-C-IRMS.
-30 minute to 8 hours after the meal

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 19, 2019

Primary Completion (Actual)

May 30, 2020

Study Completion (Actual)

May 30, 2020

Study Registration Dates

First Submitted

July 16, 2019

First Submitted That Met QC Criteria

August 27, 2019

First Posted (Actual)

August 28, 2019

Study Record Updates

Last Update Posted (Actual)

June 1, 2022

Last Update Submitted That Met QC Criteria

May 31, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Proteins

Clinical Trials on Pea

3
Subscribe